FDA.reportPublic FDA data

remimazolam 20 MG Injection

RxCUI
2383946
RxNorm name
remimazolam 20 MG Injection
Display name
remimazolam 20 MG Injection
Full name
remimazolam 20 MG Injection
Term type
PSN
Status
DailyMed mapping
Updated
2026-06-04 23:38:57

RxNav Current And Historical NDCs#

RxNav current and historical NDC rows page 1 of 1 · 0 matching rows.

No records found.

UNII Substances#

UNII substance links page 1 of 1 · 0 matching rows.

No records found.

openFDA label cross-check#

OpenFDA label data provides additional search and identifier links. DailyMed’s Structured Product Label is the canonical label on FDA.report. Matching records are deduplicated before they are shown below.

Matched openFDA labels page 1 of 1 · 1 matching rows.

Brand, Generic, Manufacturer table
BrandGenericManufacturerSPL set IDEffective dateAvailable safety fieldsJoin
BYFAVOREMIMAZOLAM BESYLATEAcacia Pharma, Ltd.4e1838f2-b999-41a7-a761-d94f09aa531f2025-02-20Boxed warning, Warnings, Adverse reactionsExact identifier
rxcui: 2383946

DailyMed RxNorm Mappings#

unique DailyMed labels mapped to this RxNorm concept page 1 of 1 · 1 matching rows.

Set ID, RxNorm mappings, Terms table
Set IDRxNorm mappingsTermsSPL versionLabelEffective
4e1838f2-b999-41a7-a761-d94f09aa531fremimazolam 20 MG Injection [PSN] · remimazolam 20 MG Injection [SCD] · remimazolam 20 MG (equivalent to remimazolam besylate 27.2 MG) Injection [SY]39These highlights do not include all the information needed to use BYFAVO safely and effectively. See full prescribing information for BYFAVO. BYFAVO ® (remimazolam) for injection, for intravenous use, CIV Initial U.S. Approval: 202020250220